Global law firm Freshfields Bruckhaus Deringer (‘Freshfields’) is advising Shanghai Henlius Biotech, Inc. (‘Henlius’), a biopharmaceutical company listed on the Hong Kong Stock Exchange (Stock Code: 2696), on its proposed privatisation by Shanghai Fosun New Medicine Research Company Limited by way of merger by absorption.
The transaction is subject to various conditions, including amongst others independent shareholder approvals.
The Freshfields team was led by partners Edward Freeman, Grace Huang and David Yi, supported by senior associate Kelly Huang, and associate Haohan Li.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
